Calidi Biotherapeutics GAAP EPS of -2.21 misses by 0.53

CLDI Stock   1.48  0.03  1.99%   
Under 61% of Calidi Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Calidi Biotherapeutics suggests that many traders are alarmed. Calidi Biotherapeutics' investing sentiment shows overall attitude of investors towards Calidi Biotherapeutics.
Calidi Biotherapeutics reports Q3 GAAP EPS of -2.21, missing estimates. Get key financial updates and insights for CLDI investors.

Read at seekingalpha.com
seekingalpha News
  

Calidi Biotherapeutics Fundamental Analysis

We analyze Calidi Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calidi Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calidi Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

Calidi Biotherapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Calidi Biotherapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Calidi Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Calidi Biotherapeutics could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics with similar companies.

Complementary Tools for Calidi Stock analysis

When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum